Abstract
The identification of novel signalling pathways in a tissue provides new avenues for pharmacological manipulation of tissue function. Where the pathway concerned is one that has been the subject of extensive research in another body system, progress towards new therapies can be rapid. The discovery that glutamate has functions in bone that share striking similarities with its role in synaptic neurotransmission opens the way to manipulate skeletal pathophysiology using modulators of glutamate release, uptake or receptor function. The purpose of this review is to describe the way that a role for glutamate as a signalling molecule in bone was discovered, to summarise the evidence for this role. In addition, it will identify points that are unresolved, to highlight areas where new research could provide significant advances. Furthermore, it will indicate how studies already performed but analysed without consideration of the non-neuronal functions of modulators of glutamate signalling, could contain information of significant value for the advance of therapeutic approaches to bone diseases.
Keywords: Glutamate Signalling, Bone, NEURONAL GLUTAMATE SIGNALLING, OSTEOBLASTSOSTEOBLASTS
Current Pharmaceutical Design
Title: Glutamate Signalling in Bone.
Volume: 7 Issue: 8
Author(s): T. M. Skerry and A. F. Taylor
Affiliation:
Keywords: Glutamate Signalling, Bone, NEURONAL GLUTAMATE SIGNALLING, OSTEOBLASTSOSTEOBLASTS
Abstract: The identification of novel signalling pathways in a tissue provides new avenues for pharmacological manipulation of tissue function. Where the pathway concerned is one that has been the subject of extensive research in another body system, progress towards new therapies can be rapid. The discovery that glutamate has functions in bone that share striking similarities with its role in synaptic neurotransmission opens the way to manipulate skeletal pathophysiology using modulators of glutamate release, uptake or receptor function. The purpose of this review is to describe the way that a role for glutamate as a signalling molecule in bone was discovered, to summarise the evidence for this role. In addition, it will identify points that are unresolved, to highlight areas where new research could provide significant advances. Furthermore, it will indicate how studies already performed but analysed without consideration of the non-neuronal functions of modulators of glutamate signalling, could contain information of significant value for the advance of therapeutic approaches to bone diseases.
Export Options
About this article
Cite this article as:
Skerry M. T. and Taylor F. A., Glutamate Signalling in Bone., Current Pharmaceutical Design 2001; 7 (8) . https://dx.doi.org/10.2174/1381612013397771
DOI https://dx.doi.org/10.2174/1381612013397771 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology Fundamentals of Prion Diseases and Their Involvement in the Loss of Function of Cellular Prion Protein
Protein & Peptide Letters Follistatin-like 1 in Cardiovascular Disease and Inflammation
Mini-Reviews in Medicinal Chemistry Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Substrate Reduction Therapies for Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Discrimination of Active and Weakly Active Human BACE1 Inhibitors Using Self-Organizing Map and Support Vector Machine
Combinatorial Chemistry & High Throughput Screening “Oxygen Supply” as Modulator of Aging Processes: Hypoxia and Hyperoxia Models for Aging Studies
Current Aging Science C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Procedure for Identification and Characterization of Drugs Efficient Against Mammalian Prion: From a Yeast-Based Antiprion Drug Screening Assay to In Vivo Mouse Models
Infectious Disorders - Drug Targets Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Targeting the Pathological Hallmarks of Alzheimer’s Disease Through Nanovesicleaided Drug Delivery Approach
Current Drug Metabolism